MacLaughlin DT - Search Results

1

Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.

Donahoe PK, Clarke T, Teixeira J, Maheswaran S, MacLaughlin DT. Donahoe PK, et al. Among authors: maclaughlin dt. Mol Cell Endocrinol. 2003 Dec 15;211(1-2):37-42. doi: 10.1016/j.mce.2003.09.009. Mol Cell Endocrinol. 2003. PMID: 14656474 Review.

2

Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.

Segev DL, Hoshiya Y, Hoshiya M, Tran TT, Carey JL, Stephen AE, MacLaughlin DT, Donahoe PK, Maheswaran S. Segev DL, et al. Among authors: maclaughlin dt. Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):239-44. doi: 10.1073/pnas.221599298. Epub 2002 Jan 2. Proc Natl Acad Sci U S A. 2002. PMID: 11773638 Free PMC article.

3

New approaches for high-yield purification of Müllerian inhibiting substance improve its bioactivity.

Lorenzo HK, Teixeira J, Pahlavan N, Laurich VM, Donahoe PK, MacLaughlin DT. Lorenzo HK, et al. Among authors: maclaughlin dt. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 5;766(1):89-98. doi: 10.1016/s0378-4347(01)00436-4. J Chromatogr B Analyt Technol Biomed Life Sci. 2002. PMID: 11820299

4

Measurement of Mullerian inhibiting substance facilitates management of boys with microphallus and cryptorchidism.

Misra M, MacLaughlin DT, Donahoe PK, Lee MM. Misra M, et al. Among authors: maclaughlin dt. J Clin Endocrinol Metab. 2002 Aug;87(8):3598-602. doi: 10.1210/jcem.87.8.8742. J Clin Endocrinol Metab. 2002. PMID: 12161481

5

Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo.

Stephen AE, Pearsall LA, Christian BP, Donahoe PK, Vacanti JP, MacLaughlin DT. Stephen AE, et al. Among authors: maclaughlin dt. Clin Cancer Res. 2002 Aug;8(8):2640-6. Clin Cancer Res. 2002. PMID: 12171896

6

The role of Müllerian inhibiting substance in the evaluation of phenotypic female patients with mild degrees of virilization.

Misra M, MacLaughlin DT, Donahoe PK, Lee MM. Misra M, et al. Among authors: maclaughlin dt. J Clin Endocrinol Metab. 2003 Feb;88(2):787-92. doi: 10.1210/jc.2002-020889. J Clin Endocrinol Metab. 2003. PMID: 12574214

7

Mullerian inhibiting substance: an update.

MacLaughlin DT, Donahoe PK. MacLaughlin DT, et al. Adv Exp Med Biol. 2002;511:25-38; discussion 38-40. doi: 10.1007/978-1-4615-0621-8_3. Adv Exp Med Biol. 2002. PMID: 12575754 Review.

8

MIS/AMH in the assessment of cryptorchidism and intersex conditions.

Lee MM, Misra M, Donahoe PK, MacLaughlin DT. Lee MM, et al. Among authors: maclaughlin dt. Mol Cell Endocrinol. 2003 Dec 15;211(1-2):91-8. doi: 10.1016/j.mce.2003.09.014. Mol Cell Endocrinol. 2003. PMID: 14656481 Review.

9

Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.

Barbie TU, Barbie DA, MacLaughlin DT, Maheswaran S, Donahoe PK. Barbie TU, et al. Among authors: maclaughlin dt. Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15601-6. doi: 10.1073/pnas.2636900100. Epub 2003 Dec 11. Proc Natl Acad Sci U S A. 2003. PMID: 14671316 Free PMC article.

10

Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.

Renaud EJ, MacLaughlin DT, Oliva E, Rueda BR, Donahoe PK. Renaud EJ, et al. Among authors: maclaughlin dt. Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):111-6. doi: 10.1073/pnas.0407772101. Epub 2004 Dec 23. Proc Natl Acad Sci U S A. 2005. PMID: 15618407 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

124 results

Search Page

Filters